Clinical Research Directory
Browse clinical research sites, groups, and studies.
BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation
Sponsor: Sydney Local Health District
Summary
The goal of this open label randomised clinical trial is to compare Bivalirudin versus Heparin for anticoagulation in patients requiring extracorporeal membrane oxygenation support. The main question it aims to answer are include the ability to maintain anticoagulation within defined therapeutic range, bleeding and thrombotic complications and a comparison of the total cost of anticoagulation care. Participants will be randomised to either anticoagulation with Bivalirudin or anticoagulation with Unfractionated Heparin.
Official title: BivaLirudin versUS Heparin in ECMO - A Registry-embedded, Randomised, Open Label, Feasibility Trial Comparing Two Anticoagulation Strategies in Patients on Extracorporeal Membrane Oxygenation (ECMO)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-05-01
Completion Date
2026-05-01
Last Updated
2024-08-13
Healthy Volunteers
No
Interventions
Unfractionated heparin
Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
Bivalirudin
Bivalirudin protocol with target aPTT 50-70 seconds
Locations (1)
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia